Pliant Therapeutics Competitors

Hutchison China MediTech (NASDAQ:HCM) and Pliant Therapeutics (NASDAQ:PLRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Hutchison China MediTech and Pliant Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 79.5% of Pliant Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Hutchison China MediTech and Pliant Therapeutics, as provided by MarketBeat.com.

Hutchison China MediTech presently has a consensus target price of $40.00, indicating a potential upside of 36.75%. Pliant Therapeutics has a consensus target price of $45.50, indicating a potential upside of 52.02%. Given Pliant Therapeutics' higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Hutchison China MediTech.

Earnings & Valuation

This table compares Hutchison China MediTech and Pliant Therapeutics' revenue, earnings per share and valuation.

Pliant Therapeutics has lower revenue, but higher earnings than Hutchison China MediTech.

Summary

Pliant Therapeutics beats Hutchison China MediTech on 7 of the 9 factors compared between the two stocks.

Pliant Therapeutics (NASDAQ:PLRX) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Pliant Therapeutics and Emergent BioSolutions' net margins, return on equity and return on assets.

Insider & Institutional Ownership

79.5% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are owned by institutional investors. 14.1% of Emergent BioSolutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Pliant Therapeutics and Emergent BioSolutions, as provided by MarketBeat.com.

Pliant Therapeutics currently has a consensus target price of $45.50, indicating a potential upside of 52.02%. Emergent BioSolutions has a consensus target price of $113.6667, indicating a potential upside of 46.40%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Emergent BioSolutions.

Valuation and Earnings

This table compares Pliant Therapeutics and Emergent BioSolutions' top-line revenue, earnings per share (EPS) and valuation.

Emergent BioSolutions has higher revenue and earnings than Pliant Therapeutics.

Summary

Emergent BioSolutions beats Pliant Therapeutics on 6 of the 10 factors compared between the two stocks.

Pliant Therapeutics (NASDAQ:PLRX) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Pliant Therapeutics and I-Mab's net margins, return on equity and return on assets.

Insider & Institutional Ownership

79.5% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of I-Mab shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Pliant Therapeutics and I-Mab, as provided by MarketBeat.com.

Pliant Therapeutics currently has a consensus target price of $45.50, indicating a potential upside of 52.02%. I-Mab has a consensus target price of $70.00, indicating a potential upside of 22.81%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than I-Mab.

Valuation and Earnings

This table compares Pliant Therapeutics and I-Mab's top-line revenue, earnings per share (EPS) and valuation.

Pliant Therapeutics has higher revenue and earnings than I-Mab.

Summary

Pliant Therapeutics beats I-Mab on 8 of the 9 factors compared between the two stocks.

Pliant Therapeutics (NASDAQ:PLRX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Pliant Therapeutics and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

79.5% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Pliant Therapeutics and Arena Pharmaceuticals, as provided by MarketBeat.com.

Pliant Therapeutics currently has a consensus target price of $45.50, indicating a potential upside of 52.02%. Arena Pharmaceuticals has a consensus target price of $92.80, indicating a potential upside of 40.82%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Arena Pharmaceuticals.

Valuation and Earnings

This table compares Pliant Therapeutics and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Pliant Therapeutics.

Pliant Therapeutics (NASDAQ:PLRX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Pliant Therapeutics and Agios Pharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

79.5% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are owned by institutional investors. 3.2% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pliant Therapeutics and Agios Pharmaceuticals, as provided by MarketBeat.com.

Pliant Therapeutics currently has a consensus price target of $45.50, suggesting a potential upside of 52.02%. Agios Pharmaceuticals has a consensus price target of $64.6364, suggesting a potential upside of 18.19%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Pliant Therapeutics is more favorable than Agios Pharmaceuticals.

Earnings & Valuation

This table compares Pliant Therapeutics and Agios Pharmaceuticals' top-line revenue, earnings per share and valuation.

Pliant Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals.

Summary

Pliant Therapeutics beats Agios Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Pliant Therapeutics (NASDAQ:PLRX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Pliant Therapeutics and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

79.5% of Pliant Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pliant Therapeutics and Atea Pharmaceuticals, as provided by MarketBeat.com.

Pliant Therapeutics currently has a consensus price target of $45.50, suggesting a potential upside of 52.02%. Atea Pharmaceuticals has a consensus price target of $69.3333, suggesting a potential upside of 54.28%. Given Atea Pharmaceuticals' higher possible upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Pliant Therapeutics.

Earnings & Valuation

This table compares Pliant Therapeutics and Atea Pharmaceuticals' top-line revenue, earnings per share and valuation.

Atea Pharmaceuticals has lower revenue, but higher earnings than Pliant Therapeutics.

Summary

Pliant Therapeutics beats Atea Pharmaceuticals on 6 of the 7 factors compared between the two stocks.